Understanding The Critical Role Of Developability Assessments To Enable Effective Lead Candidate Selection

Biological candidates are often selected based on their activity and functionality, while other critical factors such as manufacturability and immunogenicity receive less attention. This oversight in the early stages of drug development can leave developers vulnerable, potentially advancing suboptimal candidates toward clinical trials. A comprehensive understanding of a molecule’s full range of characteristics is essential to ensure that only the most promising candidates move forward.

Developability assessments play a key role in this process by evaluating the likelihood that a biologic or bioconjugate can be manufactured, will be safe, and will demonstrate efficacy. When applied effectively, these assessments increase the probability of achieving regulatory approval.

Abzena’s drug development experts offer valuable insights into how advanced scientific methods, cutting-edge technologies, and deep expertise in biologics can be harnessed to provide robust developability solutions. This approach supports the development of optimal drug candidates by enabling early risk mitigation, informed decision-making, and a higher chance of clinical success.